// App-Quantinova.ai

AB0524 (2021) : EFFICACY OF GUSELKUMAB ACROSS BASDAI COMPONENTS IN TREATING AXIAL-RELATED SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES

Researchers

Presenter

  • F. Behrens

Principal Investigators

  • P. J. Mease

  • P. Helliwell

  • M. Shawi

  • W. Noel

  • S. D. Chakravarty

  • A. Kollmeier

  • X. L. Xu

  • S. Xu

  • Y. Wang

  • X. Baraliakos

Medical Centers

  • Goethe University, Rheumatology and Fraunhofer Institute Translational Medicine and Pharmacology ITMP, Frankfurt, Germany

  • 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • , Janssen Global Services, LLC, Horsham, PA, United States of America

  • Janssen Scientific Affairs, LLC, Immunology, Brussels, Belgium

  • Janssen Scientific Affairs, LLC, Immunology, Horsham, United States of America

  • Drexel University College of Medicine, Rheumatology, Philadelphia, United States of America

  • Janssen Research & Development, LLC, Immunology, San Diego, CA, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Bochum, Germany

Locations

  • United States

  • United Kingdom

  • Belgium

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Sacroiliitis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Celgene

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved